Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Debt (2022 - 2025)

BioXcel Therapeutics has reported Total Debt over the past 4 years, most recently at $109.6 million for Q4 2025.

  • Quarterly results put Total Debt at $109.6 million for Q4 2025, up 6.91% from a year ago — trailing twelve months through Dec 2025 was $109.6 million (up 6.91% YoY), and the annual figure for FY2025 was $109.6 million, up 6.91%.
  • Total Debt for Q4 2025 was $109.6 million at BioXcel Therapeutics, roughly flat from $109.1 million in the prior quarter.
  • Over the last five years, Total Debt for BTAI hit a ceiling of $109.6 million in Q4 2025 and a floor of $56000.0 in Q1 2022.
  • Median Total Debt over the past 4 years was $101.1 million (2023), compared with a mean of $92.8 million.
  • Biggest five-year swings in Total Debt: skyrocketed 170332.14% in 2023 and later rose 1.9% in 2024.
  • BioXcel Therapeutics' Total Debt stood at $93.5 million in 2022, then increased by 7.62% to $100.6 million in 2023, then rose by 1.9% to $102.5 million in 2024, then grew by 6.91% to $109.6 million in 2025.
  • The last three reported values for Total Debt were $109.6 million (Q4 2025), $109.1 million (Q3 2025), and $108.7 million (Q2 2025) per Business Quant data.